Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,regularMarketChangePercent,regularMarketDayRange,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,FUSN,279071000.0,42456600,10716000,,-17536000,,-17529000,6964000,0,-17680000,-17680000,,,,,,-7000,0,17680000,0,144000,,-17529000,-17529000,409520000.0,18237000.0,279071000.0,1216000.0,297308000.0,1147000.0,-130732000.0,4295000.0,283000.0,2396000.0,41070000.0,7618000.0,653000.0,283000.0,10060000.0,233855000.0,50997000.0,186150000.0,979000.0,1018000.0,-28414000.0,-2346000.0,-28998000.0,130000.0,-657000.0,130000.0,-49447000.0,17000.0,-20596000.0,111000.0,2408000.0,-584000.0,,226237000.0,en-US,US,EQUITY,True,Delayed Quote,NMS,USD,9.08,1630526403,-0.25,9.205,9.41,8.96,34194,9.33,8.46,9.63,8,18,finmb_421477092,NasdaqGS,Fusion Pharmaceuticals Inc.,USD,73568,68933,2.473,0.3743,6.607 - 13.89,-4.8100004,-0.34629232,6.607,13.89,1620718204,1628506740,1628856000,POST,us_market,Fusion Pharmaceuticals Inc.,0,False,False,2,-2.6795285,8.96 - 9.41,-2.19,-4.1461186,8.237638,0.84236145,0.10225764,9.171812,-0.091812134,-0.01001025,390342848,15,America/New_York,EDT,-14400000,,,,13.89,6.61,8.24,9.17,73.57k,68.93k,42.46M,,22.24M,9.05%,80.40%,253.53k,8.94,0.61%,0.60%,219.87k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-15.82%,-50.76%,,,,,-46.49M,-85.64M,,,227.22M,5.35,7.52M,2.69,30.70,,-42.74M,-31.35M,Value,L8P 0A6,Healthcare,51,"Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.",Hamilton,289 799 0891,ON,1609372800,Canada,http://fusionpharma.com,86400,270 Longwood Road South,Biotechnology
t-1,FUSN,294513000.0,42456600,4960000,,-10801000,,-13385000,6639000,0,-11599000,-11599000,,,,,,2584000,0,11599000,0,798000,,-13385000,-13385000,407672000.0,16163000.0,294513000.0,3799000.0,310676000.0,1152000.0,-113203000.0,4306000.0,44000.0,3463000.0,90517000.0,11857000.0,653000.0,44000.0,1967000.0,228164000.0,77082000.0,131882000.0,794000.0,3399000.0,-155044000.0,7408000.0,-155104000.0,56000.0,-1219000.0,56000.0,-158130000.0,17000.0,-3082000.0,109000.0,1203000.0,-60000.0,,216307000.0,en-US,US,EQUITY,True,Delayed Quote,NMS,USD,9.08,1630526403,-0.25,9.205,9.41,8.96,34194,9.33,8.46,9.63,8,18,finmb_421477092,NasdaqGS,Fusion Pharmaceuticals Inc.,USD,73568,68933,2.473,0.3743,6.607 - 13.89,-4.8100004,-0.34629232,6.607,13.89,1620718204,1628506740,1628856000,POST,us_market,Fusion Pharmaceuticals Inc.,0,False,False,2,-2.6795285,8.96 - 9.41,-2.19,-4.1461186,8.237638,0.84236145,0.10225764,9.171812,-0.091812134,-0.01001025,390342848,15,America/New_York,EDT,-14400000,,,,13.89,6.61,8.24,9.17,73.57k,68.93k,42.46M,,22.24M,9.05%,80.40%,253.53k,8.94,0.61%,0.60%,219.87k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-15.82%,-50.76%,,,,,-46.49M,-85.64M,,,227.22M,5.35,7.52M,2.69,30.70,,-42.74M,-31.35M,Value,L8P 0A6,Healthcare,51,"Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.",Hamilton,289 799 0891,ON,1609372800,Canada,http://fusionpharma.com,86400,270 Longwood Road South,Biotechnology
t-2,FUSN,306454000.0,42456600,4529000,,-10178000,,-9993000,5790000,0,-10319000,-10319000,,,,,,-185000,0,10319000,0,141000,,-9993000,-9993000,406273000.0,5605000.0,306454000.0,,312059000.0,732000.0,-99818000.0,296000.0,-1000.0,2092000.0,248793000.0,5309000.0,106000.0,-1000.0,1981000.0,296884000.0,11102000.0,43159000.0,891000.0,956000.0,-54286000.0,469000.0,-54967000.0,-2296000.0,-4394000.0,56000.0,-70131000.0,17000.0,-12868000.0,103000.0,1226000.0,-681000.0,-2296000.0,291575000.0,en-US,US,EQUITY,True,Delayed Quote,NMS,USD,9.08,1630526403,-0.25,9.205,9.41,8.96,34194,9.33,8.46,9.63,8,18,finmb_421477092,NasdaqGS,Fusion Pharmaceuticals Inc.,USD,73568,68933,2.473,0.3743,6.607 - 13.89,-4.8100004,-0.34629232,6.607,13.89,1620718204,1628506740,1628856000,POST,us_market,Fusion Pharmaceuticals Inc.,0,False,False,2,-2.6795285,8.96 - 9.41,-2.19,-4.1461186,8.237638,0.84236145,0.10225764,9.171812,-0.091812134,-0.01001025,390342848,15,America/New_York,EDT,-14400000,,,,13.89,6.61,8.24,9.17,73.57k,68.93k,42.46M,,22.24M,9.05%,80.40%,253.53k,8.94,0.61%,0.60%,219.87k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-15.82%,-50.76%,,,,,-46.49M,-85.64M,,,227.22M,5.35,7.52M,2.69,30.70,,-42.74M,-31.35M,Value,L8P 0A6,Healthcare,51,"Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.",Hamilton,289 799 0891,ON,1609372800,Canada,http://fusionpharma.com,86400,270 Longwood Road South,Biotechnology
t-3,FUSN,315207000.0,42456600,3325000,,-44583000,,-44733000,3988000,0,-7313000,-7313000,,,,,,150000,0,7313000,0,-37270000,,-44733000,-44733000,405032000.0,7903000.0,315207000.0,278000.0,323110000.0,656000.0,-89825000.0,293000.0,,1575000.0,318892000.0,7610000.0,78000.0,,1403000.0,320132000.0,,,411000.0,703000.0,-54286000.0,-1177000.0,-168000.0,257840000.0,1412000.0,197625000.0,251475000.0,17000.0,-6197000.0,98000.0,38103000.0,-168000.0,4446000.0,312522000.0,en-US,US,EQUITY,True,Delayed Quote,NMS,USD,9.08,1630526403,-0.25,9.205,9.41,8.96,34194,9.33,8.46,9.63,8,18,finmb_421477092,NasdaqGS,Fusion Pharmaceuticals Inc.,USD,73568,68933,2.473,0.3743,6.607 - 13.89,-4.8100004,-0.34629232,6.607,13.89,1620718204,1628506740,1628856000,POST,us_market,Fusion Pharmaceuticals Inc.,0,False,False,2,-2.6795285,8.96 - 9.41,-2.19,-4.1461186,8.237638,0.84236145,0.10225764,9.171812,-0.091812134,-0.01001025,390342848,15,America/New_York,EDT,-14400000,,,,13.89,6.61,8.24,9.17,73.57k,68.93k,42.46M,,22.24M,9.05%,80.40%,253.53k,8.94,0.61%,0.60%,219.87k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-15.82%,-50.76%,,,,,-46.49M,-85.64M,,,227.22M,5.35,7.52M,2.69,30.70,,-42.74M,-31.35M,Value,L8P 0A6,Healthcare,51,"Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.",Hamilton,289 799 0891,ON,1609372800,Canada,http://fusionpharma.com,86400,270 Longwood Road South,Biotechnology
